The Bacillus Calmette-Guérin (BCG) is a live attenuated vaccine which is recommended for neonates in countries with a high incidence of tuberculosis. The BCG vaccine has strongest non-specific effects on immune response particularly T cell-dependent immunity [@bib0030]. According to review of the literatures, the BCG has beneficial results in reduction of respiratory infections during various clinical trials. The BCG vaccination also protects from influenza A virus, herpes simplex virus type 2 (HSV2), yellow fever, mengovirus, as well as bladder cancer [@bib0035], [@bib0040].

The BCG vaccine ameliorates induction of pro-inflammatory cytokines which is named as trained immunity; it can influence heterogeneous immune response by epigenetic reprogramming such as support of IL-1β, TNF-α and IL-6 against viral infection [@bib0035], [@bib0040], [@bib0045]. Recently, as we live in a pandemic era with Covid-19 which is caused by SARS-CoV 2, several evidence suggest that the BCG vaccination protects against COVID-19; for example:•BCG vaccinated neonates are more resistant to SARS-CoV 2 infection;•there is a reduction in mortality rates in BCG implemented countries;•BCG vaccination shows efficiency against viral respiratory infections [@bib0040], [@bib0045], [@bib0050].

In recently days, it has been suggested that the BCG vaccine can be used for the reduction of mortality caused by SARS-CoV 2 and for the protection of health-care workers against COVId-19. There are fourteen registered clinical trials for evaluation of BCG vaccine against COVID-19; but clinical trials studies take more time.

We provided the present study to evaluate the clinical efficiency of BCG vaccination against SARS-CoV 2.

We obtained COVID-19 reported data from European countries using the worldometer (<https://www.worldometers.info/coronavirus/>) up to 20-July-2020. Subsequently, data converted between two groups using BCG World Atlas Database site (SARS-CoV2 in BCG recommended vs. Non-BCG recommended European countries. The abundance of total deaths and recovered cases were extracted in [table I](#tbl0005){ref-type="table"} . Also, we showed beneficial effects of BCG vaccination against COVID-19 by event rate and odds ratio.Table IStatistics of COVID-19 in European countries.Statistiques de Covid dans les pays européens.Table ICountriesCOVID-19 infected casesTotal deathsRecovered casesSARS-CoV 2 infection in non-BCG implemented countries Spain307,33528,420NA UK294,79245,300NA Italy244,43435,045196,949 Germany202,8459163187,800 Belgium63,893980017,289 Netherlands51,7256136NA Switzerland33,591196930,300 Denmark13,17361112,209 Norway90282558138 Luxembourg56051114333 Iceland1930101907 Andorra88052803 San Marino69942656 Channel Islands58347529 Isle of Man33624312 Faeroe Islands1910188 Gibraltar1800180 Liechtenstein86181 Vatican City12012Total1,231,318136,986461,686Average64,806721028,855Event rate--12% (11.9--12)78% (77.9--78.1)SARS-CoV 2 infection in BCG implemented countries Russia771,54612,342550,344 France174,67430,15279,233 Sweden77,2815619NA Belarus66,09549958,204 Ukraine58,842148530,879 Portugal48,636168933,369 Poland40,104162430,292 Romania37,458202622,617 Ireland25,760175323,364 Moldova20,98068414,376 Serbia20,89447214,047 Austria19,65571117,599 Czech13,9453598761 Macedonia91534224810 Bulgaria87333004106 Bosnia and Herzegovina83402493669 Finland73353286880 Croatia43451203018 Hungary43395963232 Albania40901122311 Greece40071941374 Montenegro218832385 Estonia2021691912 Slovakia1979281530 Lithuania1947801601 Slovenia19461121568 Latvia1192311,022 Malta6779662 Monaco109498Total1,438,27162,101921,263Average49,596214132,902Event rate--6.9% (6.8--6.9)66.6% (66.5--66.7)

We founded that there are 19 European COVID-19 regions with non-BCG implemented countries versus 29 countries with BCG implemented in Europe. The incidence of COVID-19 was higher in BCG implemented European countries; and the number of recovered cases (recovered from COVID-19) was higher in these countries and the total number of death was lower in comparison with non-BCG. There is a significant reduction in the number of total recovered cases in BCG implemented countries (OR: 2.970; 2.956-2.985 with 95% confidence intervals; *P*-value: 0.001). Also, we showed that BCG vaccination can reduce mortality caused by SARS-CoV 2 (OR: 0.360; 0.357-0.364 with 95% confidence intervals; *P*-value: 0.001).

In summary, the BCG vaccine has beneficial effects on the development of immune system. It has been suggested that the BCG vaccine has clinical benefit in protection from viral pneumonia due to the efficiency of BCG vaccine in protection from respiratory tracts infections. Recently, there are numerous registered trials for evaluation of BCG vaccine against SARS-CoV 2. We provided novel evidence to show the efficiency of BCG vaccine against SARS-CoV 2. We founded that the BCG vaccine has significantly reduced mortality caused by SARS-CoV 2. In addition, we showed that the incidence of recovered cases was significantly increased in BCG implemented countries compared with non-BCG implemented European countries. However, we need further investigation and completion of clinical trials to confirmed our presented findings.
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